AGEN · XBRL financial data

Agenus financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AGEN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	24	year only	28	24	25	27*	24	26	30	34*	34	35
Cost of revenue	0	0*	0	0	0	0*	0	0	1	0*	0	0
Research and development	51	67*	44	37	41	34*	22	27	24	8*	12	15
General and administrative	19	21*	17	17	17	21*	16	16	11	12*	7	8
Operating income (loss)	(46)	(4)*	(33)	(30)	(32)	(26)*	(13)	(17)	(5)	14*	15	11
Interest income	—	year only	1	1	1	0*	0	0	0	0*	0	0
Interest expense	—	year only	30	32	37	21*	13	13	13	16*	15	15
Other income (expense)	—	year only	(1)	7	0	(0)*	(0)	(0)	82	(9)*	39	3
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Earnings per share, basic USD per share	(0.16)	—	(3.04)	(2.52)	(3.08)	—	(1.03)	(1.00)	2.00	—	1.03	(0.01)
Earnings per share, diluted USD per share	(0.16)	—	(3.04)	(2.52)	(3.08)	—	(1.03)	(1.00)	1.94	—	1.02	(0.01)
Weighted average shares, basic millions of shares	0	0*	20	21	22	23*	24	28	32	34*	38	41
Weighted average shares, diluted millions of shares	0	0*	20	21	22	23*	24	28	33	33*	38	41

† Share count changed about 1/20 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (AGEN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	106	76	53	94	45	40	18	10	3	3	35	19
Accounts receivable	1	26	0	1	0	0	0	1	1	2	7	15
Total current assets	126	112	60	100	50	46	23	13	134	133	95	79
Property and equipment, net	140	133	130	128	124	120	117	113	16	15	15	14
Right-of-use asset	30	30	29	29	29	27	27	26	8	8	7	7
Goodwill	25	25	25	25	25	24	24	24	24	24	24	24
Total assets	335	314	257	292	238	226	200	185	234	227	186	173
Accounts payable	41	61	51	51	46	61	64	74	85	83	71	59
Accrued liabilities	38	45	41	41	37	35	36	39	32	34	37	28
Current portion of long-term debt	0	0	14	13	13	3	1	11	11	45	30	30
Total current liabilities	198	256	256	271	271	221	208	235	287	323	249	232
Long-term debt	13	13	0	0	0	30	33	23	24	0	—	—
Lease liability, non-current	63	63	62	56	55	55	54	53	10	10	10	10
Accumulated deficit	(1,909)	(1,956)	(2,018)	(2,071)	(2,137)	(2,183)	(2,208)	(2,236)	(2,172)	(2,183)	(2,144)	(2,144)
Total stockholders' equity	(129)	(160)	(201)	(241)	(292)	(326)	(342)	(355)	(274)	(271)	(221)	(199)
Total liabilities and equity	335	314	257	292	238	226	200	185	234	227	186	173
Common shares outstanding (cover page) millions of shares	381	419	21	22	23	25	27	32	34	38	42	45

† Share count changed about 1/20 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (AGEN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Stock-based compensation	6*	5*	4	4*	5*	5*	3	4*	3*	3*	1	4*
Net cash from operating activities	(65)*	(40)*	(38)	(38)*	(53)*	(29)*	(26)	(20)*	(15)*	(17)*	(36)	(31)*
Purchases of property and equipment	3*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from investing activities	12*	3*	0	(0)*	0*	(0)*	0	0*	0*	1*	69	0*
Proceeds from issuing equity	20*	10*	17	2*	7*	7*	6	12*	9*	9*	1	14*
Repayments of long-term debt	—	—	—	—	0*	—	3	0*	0*	0*	8	0*
Net cash from financing activities	18*	7*	15	79*	5*	24*	4	11*	7*	15*	(1)	15*
Net change in cash	(36)*	(30)*	(23)	41*	(49)*	(4)*	(22)	(9)*	(8)*	(0)*	32	(16)*

† Share count changed about 1/20 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Agenus	19	35	(31)*	45.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Vistagen Therapeutics	17	not reported	(15)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Skye Bioscience	8.1	not reported	(7.1)*	35.4M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	36	3.2	(26)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6.8	not reported	(23)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	37	57	1.6*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Neurogene	112	not reported	(24)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19	1.6	(20)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41	6.1	(6.9)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.